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The integration of Personalized medicine (PM) into mainstream healthcare will only be 
successful if the public understand and support this change. The aim was to understand the 
public perception of the barriers and facilitators towards the use of PM. A mixed methods 
systematic review of the literature was conducted within six databases from 2006 to present. 
Twenty-one studies with 9507 participants were included. The key themes were familiarity 
and willingness to use PM, perceived benefits and perceived risks of PM. The review shows 
that, despite a limited familiarity of the underlying principles, the public is generally 
enthusiastic about the introduction of PM. The study defines areas where progress can be 
made to enhance this understanding and address legitimate concerns.  
 
Introduction 
The international Human Genome Project began in the 1990s to produce the first DNA 
sequence of the entire reference human genome [1, 2]. The sequencing of the human 
genome provides new insights that explain the causation and severity of human diseases 
and predict individual responses to medication [2].  The Human Genome project has 
provided the foundation to translate genomic information into health benefits in the form of 
PM. This emerging PM approach aims to deliver targeted treatments, based on an 
individuals’ genetics aims to improve treatment efficacy and reducing the risk of adverse 
effects [2, 3]. Leaders of countries and large healthcare organisations are urging a rapid 
translation of these discoveries into benefit for patients [4, 5].  However, the conversion to 
“an innovative approach that takes into account individual differences in people’s genes, 
environments, and lifestyles” [5] from the existing “one-size-fits-all” approach in healthcare 
will require a better understanding of this new approach by the general public and other 
stake-holders [6].  
  
PM is a term which has been adopted within the literature and within clinical practice with a 
varied number of definitions. The subjectivity when defining PM has been recognised by 
Schleidgen et al, who performed a systematic literature review to produce a precise 
definition: “PM seeks to improve stratification and timing of health care by utilizing biological 
information and biomarkers on the level of molecular disease pathways, genetics, 
proteomics as well as metabolomics” [5]. Other publications have viewed 
pharmacogenetics/genomics (PGx) as the foundation of personalized medicine and thus 
solely focused on PGx when measuring opinion on personalized medicine. For the purpose 
of this literature review the authors have followed the National Institute of Health (NIH) 
definition of PM as an “approach for disease treatment and prevention that takes into 
account individual variability in genes, environment, and lifestyle for each person” [7].  
 
With an increasing appreciation that PM will only become successful with public acceptance 
and participation [8], there is now an extensive body of literature regarding the public’s 
attitude and opinion regarding PM. However, while the last decade represents a critically 
important period in the history of development and maturation of PM, our searches of 6 
databases could not identify any systematic reviews on this subject since 2006 [9]. The last 
systematic review of the public perspective of PM by Nielsen and Moldrup was published in 
2006 and focused mainly on pharmacogenomics [9]. This reveals a significant knowledge 
gap regarding the public’s views on PM. It is thus currently difficult to fully appreciate the 
public’s views about PM against the context of the very positive views expressed by 
government and opinion leaders. We do not have a holistic understanding of the concerns 
regarding PM within the public. Overall, this lack of knowledge makes it difficult to design 
public engagement activities in this field that are based on an up-to-date understanding of 
public opinion. There is thus a need for a detailed systematic review of publications in this 




A search of the literature was conducted in February 2018 using 6 databases (Medline, 
Embase, Cinhal, BNI and Psycinfo). Terms for PM were searched in conjunction with terms 
relating to public opinion (see appendix 1 for full search strategy). The search was restricted 
to papers published from 2006-2018, to capture the effect of the most recent advances in 
genomics and PM on public perception. Editorials, conference abstract or reviews were 
excluded from the review. In addition, papers were identified from references of selected 
articles that were relevant and met the inclusion criteria.  
 
Inclusion and exclusion criteria 
Studies were eligible if they included an aim or objective relating to the public’s opinion of 
PM and if at least one group of participants were members of the public. Studies with both 
quantitative and qualitative study designs were included. Studies were excluded from the 
review that were editorials, conference abstract, reviews and commentaries and if it was 
published before 2006. The full inclusion and exclusion criteria can be seen in appendix 2. 
 
Study selection and data extraction 
The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
summarises the systematic review process used (see figure 1). Data was extracted using a 
proforma before qualitative synthesis was carried out using a thematic approach that was 
independently adopted by two of the authors. The methodology, including the research 
question, search strategy, inclusion and exclusion criteria and risk of bias assessment, was 






Figure 1. Prisma diagram for the inclusion of studies reporting public opinion of PM.  
 
Assessment of study quality 
The mixed methods appraisal tool (MMAT) 2011 version [10] was applied to each study by 
the authors to give an assessment of the methodological quality. The MMAT was chosen as 
it was designed for the appraisal stage of a complex systematic review that includes 
quantitative, qualitative and mixed methods studies. The MMAT comprises of 2 screening 
questions and 4 criteria assessing the methodology that are specific to the study design. A 
score can be derived of 0% (no criteria met) to 100% (all 4 criteria met).   
 
Summary measures and data synthesis 
A qualitative thematic synthesis of results was performed. A minimum of two authors 




















































139 Excluded by title 
41 Excluded by Abstract 
 
Full-text articles assessed 
for eligibility 
(n = 32) Excluded for the following: 
-Aim/ objectives are not on public opinion of 
personalised medicine (n=6) 
-Focused on the public’s opinion regarding direct 
to consumer genetic testing (n=2) 
-Participants were not members of the public 
(n=3) 
-Full text not available in English (n=1) 
 Studies included in 
narrative synthesis  
(n = 21) 
         Qualitative =8 
         Quantitative =12 
        Mixed Methods =1 








 (n = 330) 
Records screened  
(n = 212) 
Duplicates removed (n = 118) 
 
Articles identified from 
reference list n=1 
 


























































95.9% of patients would accept 
pharmacogenomic testing prior to receiving 
a prescription for asthma medication. 
94.4% felt it would be advantageous to 
know their genetic disposition. Younger 
patients were generally more likely to be 
hopeful about the usefulness of 



























Increased knowledge of pharmacogenetics 
among participants who have experienced 
lack of effect and side effects of medicines 
and have had medical investigations. 
79.1% of participants think that society 
needs 




























14.1% of participants had heard of 
pharmacogenomics. 89% indicated 
willingness to receive pharmacogenetic 
treatment in future. 81% would choose to 
use a pharmacogenomics-directed drug 
rather than an ‘ordinary drug’. Generally 
positive attitude towards 
pharmacogenomics. No significant results 
showing that 
experiencing side effects is connected to 
the respondents’ general attitude to the use 


























Broad support for genome-based therapies 
for 
depression. Public groups felt 
pharmacogenomics was generally a good 
idea and felt positive towards it. The public 
focus group from Poland were particularly 
positive. Service users had concerns 


























Participants in all 4 focus groups 
demonstrated a limited understanding of 
the genetic basis of PM.  Majority of 
participants indicated a preference for the 
use of pharmacogenomics testing for the 
purpose of improving drug prescribing. 
Participants were concerned with issues 
surrounding privacy and confidentiality of 
genetic test results, particularly with respect 

















Age range 18- 









Majority of participants unfamiliar with the 
genetic basis of PM. Pharmacogenetic 
testing viewed as being potentially positive. 
Concerns regarding storage and privacy of 
























All focus groups shared generally positive 
views on PM with the view it has the 
potential for medication with fewer side 
effects and less ‘trial and error prescribing’. 
African American group more concerned 




and they were less likely to trust their 
health professional and therefore accept  
recommendation of PM.  
Butrick 







Mean age 47 















Overall participants found genetically 
personalised medicine as ‘comparably 
effective’ as conventional medicine but 
were reluctant to take up personalised 
medicine. Participants from an ethnic 
minority background (who were 
predominantly African American) reported 
lower adherence intention to genetically 





























51% of participants would agree for their 
child to undergo a genetic test if offered. 
Factors increasing the willingness for their 
child to undergo genetic testing were: being 
the child’s mother, perceiving the child to 
have greater disease risk and valuing 

























Approximately 66% planned to act on their 
genomic risk assessment results by making 
or planning 
lifestyle or behavioural changes. 25% were 





























After initially being told of the risks of 
pharmacogenomic (PGX) testing 65% of 
respondents were extremely/somewhat 
likely to agree to a PGX test.  
However, once informed of the benefits of 
PGX testing this increased to 82% of 
respondents showing interest. 
Experiencing a drug side-effect was 
significantly associated with likelihood of 




























Awareness of ‘personal genomics’ was 
high, 78% of those had heard of the term 
before (22.1% had never heard of personal 
genomics, 58.9% had heard a little, 18.9% 
had heard a lot). 18.9% were concerned 











Mean age 21.5. 
78% female. 











Participants were less willing to use a 
personalised medicine over a 
pharmaceutical medicine. Personalised 
medicine was not considered less harmful 













39, 29% 40-54, 
14% 55-70 









Majority felt that personalised medicine 
increases care. Concern that PM could 
lead to stratification of patients appropriate 
for certain treatments and therefore result 
in the ‘rationing of care’. Concern regarding 
discrimination from employment and 
insurance sectors. Concern of cost of PM 
and whether it is “value for money”. 
Concern health care systems and providers 































38% of patients and 60% of participants 
from general public sample were either 
‘somewhat wiling’ or ‘very willing’ to 
undergo warfarin PGX testing. Participants 
in the general public sample without a 
history of an ADR tended to be more willing 
to undergo warfarin PGX testing than those 
















36% of lay respondents misidentified what 
was meant by personalised medicine. 




ry survey g appeared to be the most important issue to 
the respondents.  Respondents who were 
more knowledgeable about PGXx were 
also more comfortable with PGXx testing. 
Eastma



















16% of respondents were informed about 
what personalised medicine is. 69% of 
respondents interested in learning more 
about PM. 77% willing to have PM if 
physician recommends it. Main concern 
access and affordability. 
25 
Lachan












Mean age public 
32.6 years. 
Patient group 1 
mean age 56.8, 
patient group 2 















90% of participants were willing to undergo 
pharmacogenomics testing if it showed 
whether a particular medicine would work 
for them. Healthy individuals were more 
concerned than the two patient groups 
regarding employment and health 
insurance discrimination and confidentiality. 
If pharmacogenomic test revealed that drug 
would be ineffective or cause severe side-
effects, less than half of participants would 































Low familiarity with the term personalised 
medicine (73% had never heard of the term 
before). Once PM explained 63% of 
participants thought personalised medicine 
would have a positive impact.  At significant 
levels (p < 0.05%) respondents who rated 
their health as very good to excellent report 
having a higher knowledge of personalized 




























45% of public aware of personalised 
medicine in USA and 33% public in 
Germany. 69% of public in USA and 54% 
German public thought PM potential to 
deliver better medical care and to become 
a medicine of the future. Age, gender, 
health insurance availability and insurance 
coverage had no influence on PM 
acceptance by the public (p > 0.05). 60% of 
public (both USA and German group) 
shared opinion that personalized drugs are 
more effective than standard drugs. 
Opinion that PM causes fewer side effects: 
public 38% in USA and 50% Germany. 
































Both groups agreed pharmacogenomics 
could inform prescribing. Concerns over 
insurance coverage and employment 
discrimination. Both groups wanted 
physicians to engage participants and to 









 In total 21 papers were included in the review. The total number of participants from the 
studies included was 9507. The number of participants in each study varied significantly, 
with a mean average of 453 participants per study and a participant range of 14- 3000 (table 
1.) Of the 21 studies, 13 included solely members of the public as participants.  
 
Data synthesis 
A qualitative synthesis of the public opinion on the barriers and facilitators to implementation 
of PM are presented as three key themes (table 2) 
  
Familiarity and willingness to use personalized medicine 
A barrier that was a common finding was that participants were unfamiliar with what PM is 
and what it involves [11-20]. Eastman et al. reported that only 16% of their participants from 
the public were familiar with the concept of PM ([19]. Issa et al. found during focus groups 
with participants, who had been recruited from outpatient clinics, that most had an 
awareness of the term PM but had a limited understanding of its genetic basis [21]. The 
public often had a different perception of what PM involved, such as thinking that it was gene 
therapy or would give the patients their disease risk for all diseases [18]. 
 
Thirteen of the papers reviewed found that participants were willing to use PM after the 
concept had been explained by the researcher [12-13, 15-17, 19, 21-26]. There was 
variability between studies on how willing participants were to accept the use of PM and 
facilitator and barriers have been identified that contribute to this. Willingness to use PM was 
as high as 96% in a paper involving patients with asthma and COPD [22] and as low as 38% 
of patients in a study evaluating willingness to undergo warfarin pharmacogenetic testing 
[27].  A facilitator identified in four studies found that people were more willing to use PM if 
their health professional offered PM as part of a shared decision-making process through 
use of good communication skills [12, 14, 19, 28]. Participants  who had previously 
experienced an adverse drug event (ADR) was found to be a facilitator in a study by Haga et 
al. [13], but Chan et al. [27] found participants without a history of an ADR were more willing 
to accept PM than those who had experienced an ADR. 
 
Sociodemographic factors that were facilitators towards the willingness to use of PM were 
identified as being a young adult [13, 22] and having a higher level of education [13, 27]. 
Individuals who described themselves as having good health were more likely to consider 
using PM [13, 15].  A barrier that was identified is that people from ethnic minority 
backgrounds were less likely to accept PM and had more concerns with its use [13, 24, 28].   
 
Perceived benefits of PM  
An important facilitator identified by eight studies found that the public, once informed about 
PM, thought that the use of PM would provide better health care and health benefits for 
patients [11, 15-16, 18, 21-22, 25, 29]. Garfield et al. found that 95% of their participants 
expected PM to have a positive impact [15]. A further facilitator is that participants thought 
that PM has the potential to improve efficacy of prescribed medication for patients [11-12, 
17, 21-22, 26].  Five studies found that the public expected PM to lead to fewer ADR’s than 
standard medicine [11, 17, 22, 24, 26]. Participants had an impression that PM would result 
in less trial and error prescribing, with one participant describing it as ‘it’s not as time 
consuming as it is if you keep going back and forth to the doctor trying to figure out what’s 
gonna work’ [24].  A further perceived benefit of PM was that it could be an economic 
advantage to society with the potential for improved health, treatment efficacy and fewer 
ADRs [11, 17]. 
 
Perceived risks of PM 
In all 21 studies, the participants raised concerns regarding the use of PM. An important 
barrier to the use of PM, raised in 11 studies, was the concern that results from genetics 
tests used for PM could lead to patients experiencing health insurance discrimination [12, 
14, 17, 21-22, 24-25, 27-28]. Participants were concerned in particular that their health 
insurance cost could increase with the use of PM and that it may not be covered by their 
insurance [12, 14, 17, 21-22, 24-25, 27-28]. Concerns regarding health insurance and PM 
varied depending on the study country and was not raised in studies in the UK, where health 
care provision is largely universal [16, 29]. The potential for employment discrimination was 
identified as another barrier for the use of PM and Lachance et al. found that this was of 
greater concern to healthy individuals than those with chronic health problems [12, 15 22, 
25-26]. A further important barrier that was raised in eight studies was a concern that 
individuals’ genetic information may not be stored confidentially and securely [14, 16, 22, 25-
26, 28, 30]. 
 
A healthcare concern with the use of PM was that its use may limit patients’ access to 
certain treatments if they were not genetically suitable for them [17, 22-23, 25]. A barrier 
identified in two studies carried out in the USA and Canada was that participants were 
concerned that the health care systems and health care providers were currently unprepared 
to implement PM [25, 30]. Bombard et al. found that participants were concerned health 
systems were unprepared particularly in the areas of laboratory genetic testing and health 
care provider’s knowledge in interpreting genetic test results [25].  
 
 
Themes of facilitator and barriers to public use of Personalized Medicine  
Facilitators                                                                                       Barriers                                                                                    
References                                                                                      References                                                   
Familiarity and willingness to use personalized medicine 
 
Relationship and interpersonal skills of HP [12, 14, 19, 28].  
 
 
Self-rated good health [13, 15]. 
 
Previous experience of an adverse drug reaction [13]. 
 
Sociodemographic factors: young adult, higher level of 
education [13, 17, 22, 27].  
Familiarity and willingness to use personalized medicine 
 
Participants unfamiliar of what PM is and what PM involves 
[11-20] 
  
Previous experience of an adverse drug reaction [27]. 
 
Sociodemographic factors: less willing to use PM if from an 
ethnic minority background [13, 24, 28]. 
 
 
Perceived benefits of PM 
 
Better health care and treatment efficacy: [11-12, 15-19, 21-
22, 25-26]. 
 
Fewer side effects/ adverse drug related events than standard 
medicine [11, 17, 22, 24, 26]. 
 
Increased knowledge about the individual patient to help 
decision making [12, 24]. 
                                                                                        
Economic advantage to society [11, 17]. 
Perceived benefits of PM 
 




Perceived risks of PM 
 
 Risk of Discrimination (employment and insurance) [12, 14-
15, 17, 21-22, 24, 25-28].  
 
Potential to limit access to certain treatments [17, 22-23, 25]. 
 
Confidentiality and safe storage of PM data 
[14, 16, 22, 25-26, 28, 30]. 
                                                                                    
Concern health care systems and providers unprepared to 
implement PM [25, 30] 
 




The need to embed personalized medicine into day-to-day health care is well-established [4, 
5]. This systematic review of 21 studies demonstrates an overall keen interest in a 
substantial proportion of more than 9000 members of the public, including patients, from 
North America, UK and continental Europe, to engage in a wider discussion on this 
important subject. The introduction of personalized medicine represents a “revolution” within 
healthcare systems [32], and the public as key stake-holders, will play a critically important 
role in its implementation. The study shows that, despite a limited understanding of the 
underlying principles, the public is generally enthusiastic about the introduction of 
personalized medicine. The study also defines areas where progress can be made to 
enhance this understanding and address legitimate concerns. Crucially, the review fails to 
identify evidence of a systematic exploration of the public’s views on personalized medicine 
in Africa, South America and Asia, where personalized medicine-related treatment 
approaches will inevitably influence the management of common diseases over the next 
decade.    
 
An important purpose of this systematic review is to understand the public’s views regarding 
personalized medicine in the context of key recent pronouncements of public policy in this 
area. To appreciate the level of commitment to personalized medicine expressed recently at 
the highest level, it may be relevant to reflect on a few recent statements of public policy in 
this regard. The following are excerpts from ex-President Obama remarks “personalized 
medicine -- gives us one of the greatest opportunities for new medical breakthroughs that we 
have ever seen --  and that’s the promise of precision medicine -- delivering the right 
treatments, at the right time, every time to the right person -- and for a small but growing 
number of patients, that future is already here [33]. Simon Stevens, chief executive of NHS 
England wants the health service to move “from mostly one-size-fits-all treatment to 
genuinely personalised care -- The NHS should be at the forefront of this global medical 
revolution” [4, 34]. This systematic review shows (table 1) that this commitment towards PM 
is broadly matched by reciprocal enthusiasm and interest for PM among most of the 
participants from North America, the UK and Continental Europe.   
 
Several important concerns and recommendations identified worldwide could help focus the 
development of PM and public engagement strategies in this regard. Firstly, the public 
prefers a holistic approach to medical practice that is maintained in tandem with the 
development of PM [14]. Thus, for example, much of the disease burden in an individual with 
asthma and allergy may result from sensitisation to particular allergens and differences in 
response to medication, and this pattern could vary greatly between individuals. The correct 
approach thus requires a wider interpretation and practice of PM, exploring disease 
heterogeneity in individuals within the context of their genetic traits, to develop personalized 
strategies for management that are underpinned by information from careful history-taking 
and appropriate investigations [35]. There is also public concern regarding costs, insurance 
and employment-related discrimination resulting from the introduction of PM into mainstream 
healthcare [12, 14-15, 17, 21-22, 24, 25-28]. Despite clear intentions at the highest levels to 
introduce PM for the benefit of society and to engage the public, there is little or no evidence 
of organisations such as the FDA or the NHS facilitating dialogue with the public to manage 
these concerns. Indeed, concern regarding discrimination at insurance and employment 
levels could represent a major barrier for recruiting people to a future national genome 
database to facilitate day-to-day care, unless specific data management rules can be 
developed through effective public consultation.  
 
Importantly, our search strategy failed to identify relevant studies from Africa or South 
America and only 1 study in Asia. Yet, any significant shift in clinical practice in North 
America and Europe is likely to influence treatment options in these continents. Public 
opinion regarding PM is also likely to be influenced by cultural influences that can vary 
between different nations. This systematic review thus points towards the need for 
exploratory studies in these continents to assess the views of the public regarding PM. 
Initially, it may be necessary to work on increasing awareness regarding PM among different 
communities and providing access to the relevant information. Subsequently, we will need to 
explore perceived benefits and concerns, which may differ across cultures.       
        
Strength and limitations   
A key strength is this is the first systematic review of the public perception of PM since 2006 
and the facilitators and barriers identified can be used by health professionals and 
researchers to engage the public and patients in PM.  
A limitation is the studies included are heterogeneous and variability in the methodology 
makes it challenging to compare the findings from each study included in this review. The 
heterogeneous nature of the studies prevented a robust statistical analysis to be carried out. 
Use of the MMAT tool allowed the authors to assess the quality of qualitative, quantitative 
and mixed methods studies, although the tool does have limitations. The MMAT tool relies 
on good quality of reporting and a lack of a methodological criterion being described in the 
paper does not necessarily mean that the criterion was not met [36] The MMAT tool 
questions to assess the qualitative papers are noted by the authors to be less precise than 
the quantitative questions.  
A further limitation within this area of research and therefore the papers within this review is 
the need to first explain the term PM to participants. There is a risk of bias at the study level 
as the facilitators will have their own fixed definition and this will be affected by their own 
personal beliefs and interests in PM. 
 
Future perspective 
The field of personalised medicine over the next 10 years is expected to continue to expand 
and be increasingly used as part of mainstream healthcare once there is an increase in 
public engagement activities in this field that are based on an up-to-date understanding of 
public opinion. It is predicted that exploratory studies will be carried out in Africa, South 
America and Asia to assess the views of the public regarding PM. 
 
Executive Summary 
• The review shows that, despite a limited familiarity of the underlying principles, the 
public is generally enthusiastic about the introduction of PM. 
• Important barriers toward the implementation of PM are the public concern regarding 
costs, insurance and employment-related discrimination. Progress can be made to 
enhance this understanding and address legitimate concerns through public 
engagement.  
• The review fails to identify evidence of a systematic exploration of the public’s views 
on personalized medicine in Africa, South America and Asia, where personalized 
medicine-related treatment approaches will inevitably influence the management of 
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Appendix 1) search strategy 
Date range used (5 years, 10 years): 2006 onwards  
limits used (gender, article/study type, etc.): none  
search terms and notes (full search strategy for database searches below): 
Relevant natural language and controlled vocabulary terms were identified, selected and 
combined. Initial search strategy reviewed and agreed upon by search requester. The 
following terms were included in the literature search: personali#ed medicine, personalized 
medicine, individuali#ed medicine, pharmacogenomics and nutrigenomics. This was 
combined with terms for public opinion/support or understand or perception or acceptance or 
awareness. 
 
Search strategies were adapted to the search facilities of the medical information resources 
used. Medline (Ovid Medline(r) epub ahead of print, in-process & other non-indexed 
citations, Ovid Medline(r) daily and Ovid Medline(r) 1946 to present) and Embase (Embase 
1974 to 2018 week 07) searched via Ovid, Cinhal, bni, Psycinfo searched via hdas, Scopus 
searched via its native interface. Final result sets were de-duplicated in endnote. 
 
Appendix 2) inclusion and exclusion criteria 
 
Inclusion criteria Exclusion criteria 
Published 2006 to current Published prior 2006 
Aim/objective of the paper was public’s 
opinion of PM/ pharmacogenetics and the 
outcomes/ results reflects this. 
Focused on the public’s opinion regarding 
biobanks 
Included secondary data Focused on the public’s opinion regarding 
direct to consumer genetic testing 
Included paper with opinions of 2 groups of 
people (once one group were members of 
the public) 
Focused on the public’s opinion regarding 
PM for research purposes only 
Written in English Written in a language other than English (as 
there was not sufficient funds or time to 
invest in translating articles) 
Study design can be quantitative or 
qualitative 
Opinion of healthcare 
professionals/researcher/ geneticist only 
 Focus of article is on genomic risk profiling 
only 
 Focus of article is on stem cell research 
 Focus of article is on the ethics  of PM 
 Excluded editorials, conference abstract, 
reviews and commentaries 
 
 No full article published (i.e. abstract only). 
 
